ESSEX BIO-TECH (01061): Multi-Dose Sodium Hyaluronate Eye Drops (0.3%) Approved for Commercialization in China

Stock News
01/09

ESSEX BIO-TECH (01061) announced that the company's indirect subsidiary, Guangdong Hanfeng Baisheng Pharmaceutical Co., Ltd., has obtained approval from the National Medical Products Administration for the registration and commercialization of multi-dose sodium hyaluronate eye drops (0.3%) within the People's Republic of China. The approved product is a multi-dose eye drop containing 0.3% (5ml:15mg) sodium hyaluronate, indicated for the treatment and relief of various endogenous eye diseases, exogenous eye diseases, and damage caused by surgery, medication, trauma, or contact lens wear.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10